Regulatory
FDA’s Patient Outreach: Finding the Ties That Bind
Is the FDA doing enough to incorporate the patient perspective in the drug review process? This was the key question considered at a panel of regulatory experts held at last week’s annual BIO International Convention in San Diego. The consensus: more needs to be done. William Looney reports ...Read more
The Key to Unlock a More Accurate and Effective Sales Call Plan - The most effective sales call plans combine robust analytics with detailed local knowledge and insights from the field. Watch this  short video
to discover how to enable your sales organization to collaborate and leverage sales reps’ knowledge to localize customer targeting, while ensuring alignment with your corporate and brand strategy.
Marketing Communications
Mastering the Language of Payers
To prosper in today’s environment, pharmaceutical companies should be investing the same effort and budget to gain insights into payers as they once devoted to physicians. There needs to be a clear understanding of the payer as customer, writes Sydney Rubin
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence –  by downloading this eBook
.
Social Media
Making the Most of Social Media (Within FDA’s New Guidelines)
The FDA’s recently published social media guidelines simply outline the proper use and behavior of pharma companies utilizing social media, just as guidelines for drug testing, marketing, and label warnings do. With these guidelines in place, Ken Ribostsky asks how pharma can work to make the most out of social media
...Read more
Legal
Will the Supreme Court Spur OTC Contraceptive Development?
One piece of fall-out from the recent Hobby Lobby decision by the U.S. Supreme Court is to generate talk of Republicans backing development of a nonprescription contraceptive pill. FDA has examined the issue as part of its effort to fix its cumbersome regulatory process for bringing new nonprescription products to market. But its history approving nonprescription contraceptives does not support optimism for any fast action, writes Jill Wechsler ...Read more
New Report
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ...Click here to order |
